| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10969050 | Vaccine | 2011 | 11 Pages |
Abstract
⺠Nasal NV VLP dry powder mucoadhesive-containing formulation induces systemic and mucosal immunity. ⺠Mucoadhesive-containing dry powder formulation stabilizes the norovirus VLP antigen. ⺠Mucoadhesive nasal dry powder vaccine exhibits superior immunogenicity over liquid formulation with adjuvant. ⺠Mucoadhesive delays mucociliary clearance in the nasal cavity, but is not immunostimulatory. ⺠The nasal dry powder formulation offers needle-free administration and better vaccine stability.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Lissette S. Velasquez, Samantha Shira, Alice N. Berta, Jacquelyn Kilbourne, Babu M. Medi, Ian Tizard, Yawei Ni, Charles J. Arntzen, Melissa M. Herbst-Kralovetz,